Searched for
MOXIFLOXACIN
CPI demands action against 'medical mafia'; calls for ethical healthcare reformsThe Communist Party of India demands action against unethical healthcare practices. They state healthcare is a social obligation, not a pro...- China's 'White Lung Syndrome' resurgence sparks concerns; here's everything you need to knowChina encounters a puzzling outbreak, prompting the reimplementation of face masks and distancing measures after a surge in "white lung syn...
- Costs of 127 medicines set to go down post NPPA's 5th price capAmong the 127 medications on the NPPA's list are paracetamol, amoxycillin, rabeprazole, and metformin. Patients frequently make use of many...
- Sun Pharma, Aurobindo slide up to 2% as firms recall products in US marketAurobindo’s scrip fell to a low of Rs 612.60, 2 per cent lower than previous close on the National Stock Exchange, while Sun Pharma’s count...
- Aurobindo, Sun Pharma recall products in US marketAccording to the latest enforcement report issued by the US Food and Drug Administration (USFDA), the US-based arm of Aurobindo Pharma is r...
- Covid-19 impact: Government panel lists essential drugs that can run outA high-level government committee, which submitted its report to the Department of Pharmaceuticals (DoP) last week, reviewed 54 drugs and s...
- Mumbai pharma company gets licence for breakthrough TB drugA global non-profit drug developer TB Alliance has tied up with domestic company Macleods Pharmaceuticals to develop and commercialise its ...
- Price of J&J’s TB drug to drop by more than halfLife-saving drug bedaquiline by US pharma company Johnson & Johnson (J&J) is now being offered at $400 per patient —over 50% cheaper than t...
- World TB Day: Over 25% TB patients in India are resistant to at least one anti-TB drug"High rates of treatment failure and deaths are associated with fluoroquinolone resistance in the Indian cohort of MDR-TB patients," stated...
- Lupin gains 4% on drug launch in USVigamox had US sales of USD 267.9 million (IMS MAT March 2017), the report added.
- Lupin advances over 3% on drug launch in USInfosys, ITC, Bharti Airtel, HDFC and Wipro were among top losers on NSE.
- Lupin launches generic conjunctivitis treatment medicine in USThe product is produced at Lupin's Pithampur manufacturing facility, it added. The medicine is generic equivalent of Novartis Corp's Vigamo...
- USFDA nods to Indian drugs up 84% in 1 yearInterestingly, the growth came during the period when biggies like Sun Pharma and Dr Reddy's had reduced filings from their plants due to c...
- Despite being on rough end, annual report from US FDA’s OGD shows Indian firms won key approvals in 2015The annual report released by the FDA’s OGD shows Indian companies have won some key approvals in the world’s biggest pharmaceuticals marke...
- TB treatment could be shortened, show trialsThe effectiveness of the four-month regimen was proved on the basis of recurrence levels, number of patients testing negative in sputum sme...
- Drug combo speeds up TB treatmentThe drug combination, known as PaMZ, killed more bacteria than standard treatment and was effective in treating drug-resistant tuberculosis.
- Dr Reddy's launches antibiotic drug in US marketAccording to IMS Health, Avelox (moxifloxacin HCl) tablets had a sales figure of approximately USD 195 millions in 2013, the release said.
- Government to ban over-the-counter sale of 92 antibioticsOver-the-counter sale of around 92 antibiotic and anti-tuberculosis drugs will be clamped down in India soon.
- New drug policy to curb misuse of antibioticsA formal proposal to create India’s first ever antibiotic policy will be submitted to the Union health ministry soon.
- Two new TB drugs enter advanced stages of clinical trialTwo new drugs against tuberculosis have reached the advanced stages of clinical trial and could be made available for use by 2012-2014.
Load More
